As COVID-19 infections rise again with the return of school, uncertainty looms over the availability of updated vaccines. Will high-risk individuals be the only ones to access them by mid-September?
Peter Marks, the FDA's Center for Biologics Evaluation and Research head, resigns amid growing concerns over measles outbreaks and vaccine misinformation. His exit raises alarms about future public health initiatives.